Back to top

Bear of the Day

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at or call 800-767-3771 ext.  9339.

Kraton Performance Polymers (KRA - Snapshot Report) recently reported its 3rd straight earnings miss, prompting analysts to revise their estimates significantly lower for both 2013 and 2014. This sent the stock to a Zacks Rank #5 (Strong Sell).

Despite the negative earnings momentum, shares of Kraton still trade at a premium to their peers on a forward P/E basis. Investors may want to wait for earnings momentum to turn around before establishing a long position.

Kraton Performance Polymers produces engineered polymers that are used in a variety of products, such as adhesives, coatings, consumer and personal care products, sealants and lubricants, and medical, packaging, automotive, paving, roofing and footwear products.

Second Quarter Results

Kraton Performance Polymers reported disappointing second quarter results on July 31. Adjusted earnings per share fell -67% year-over-year to 15 cents, missing the Zacks Consensus Estimate by 9 cents. It was the company's 3rd consecutive earnings miss.

Sales were down -11% to $334.5 million, well below the consensus of $363.0 million. The decline was driven mostly by lower butadiene prices as overall volumes were essentially unchanged. The 'Paving & Roofing' end market saw the biggest revenue drop at -19% thanks in part to wet weather. Meanwhile, the gross profit margin fell 166 basis points to 17.9% of sales.

Estimates Fall

Following the Q2 earnings miss, analysts revised their estimates significantly lower for both 2013 and 2014. This sent the stock to a Zacks Rank #5 (Strong Sell).

The Zacks Consensus Estimate for 2013 is now $0.98, down from $1.47 just 30 days ago. The 2014 consensus is currently $1.87, down from $2.13 over the same period.

You can see this dramatic drop in the company's 'Price & Consensus' chart:


Shares of Kraton currently trade around 12x 12-month forward earnings, which might sound cheap on an absolute basis, but is a premium to both the industry multiple and its historical median. Its price to cash flow ratio of 18 is also above the industry and its historical median.

The Bottom Line

With falling earnings estimates and premium valuation, investors should consider avoiding this Zacks Rank #5 (Strong Sell) stock until its earnings momentum turns around.

Todd Bunton is the Growth & Income Stock Strategist for Zacks Investment Research and Editor of the Income Plus Investor service.

Please login to or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research


Are you a new Zacks Member or a visitor to

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
BITAUTO HOLD BITA 35.33 +14.82%
ANI PHARMACE ANIP 24.79 +14.66%
E HOUSECHINA EJ 10.99 +9.24%
CANADIAN SOL CSIQ 26.97 +7.15%